Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Dexmedetomidine on Postoperative Delirium After Awake Craniotomies
Sponsor: Beijing Tiantan Hospital
Summary
Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from 10% to 60%. Previous studies suggested that frontal approach and tumor located at the temporal lobe were independent risk factors for POD after supratentorial tumor resections. Therefore, patients undergoing awake craniotomies are high-risk populations for POD. A lot of trials show that dexmedetomidine might help to reduce the incidence of delirium in patients undergoing non-cardiac surgery. However, the impact of dexmedetomidine (DEX) on POD for patients undergoing awake craniotomies remains unclear. The purpose of this study was to investigate the effect of DEX on POD in patients undergoing awake craniotomies.
Official title: Effect of Dexmedetomidine on Postoperative Delirium in Patients Undergoing Awake Craniotomies: a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2022-03-31
Completion Date
2025-12-31
Last Updated
2025-02-13
Healthy Volunteers
No
Conditions
Interventions
Dexmedetomidine
The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
0.9% saline
The 0.9% saline is administered with the same volume at the same speed as the other group.
Locations (1)
Beijing Tian Tan Hospital, Capital Medical University
Beijing, Beijing Municipality, China